Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stew Kroll

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Dermatology Reports|November 12, 2014
Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302Glen J Weiss, Karen Lewandowski, Jon Oneall, et al.
Critical Care Medicine|February 16, 2019
The authors replyRinaldo Bellomo, Stew Kroll, Lakhmir S Chawla, et al.
Journal of Critical Care|December 17, 2018
Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) dataMaria K Abril, Ashish K Khanna, Stew Kroll, et al.
Journal of Cardiothoracic and Vascular Anesthesia|September 2, 2020
Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) StudyAra Klijian, Ashish K Khanna, V Seenu Reddy, et al.
Oncology|June 1, 2011
A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcomaKristen N Ganjoo, Lee D Cranmer, James E Butrynski, et al.
Neuro-Oncology|February 8, 2018
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical studyAndrew Brenner, Richard Zuniga, Jessica D Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcomaSant P Chawla, Lee D Cranmer, Brian A Van Tine, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
Critical Care (London, England)|May 5, 2023
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trialPatrick M Wieruszewski, Rinaldo Bellomo, Laurence W Busse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesGlen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Dermatology Reports|November 12, 2014
Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302Glen J Weiss, Karen Lewandowski, Jon Oneall, et al.
Critical Care Medicine|February 16, 2019
The authors replyRinaldo Bellomo, Stew Kroll, Lakhmir S Chawla, et al.
Journal of Critical Care|December 17, 2018
Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) dataMaria K Abril, Ashish K Khanna, Stew Kroll, et al.
Journal of Cardiothoracic and Vascular Anesthesia|September 2, 2020
Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) StudyAra Klijian, Ashish K Khanna, V Seenu Reddy, et al.
Oncology|June 1, 2011
A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcomaKristen N Ganjoo, Lee D Cranmer, James E Butrynski, et al.
Neuro-Oncology|February 8, 2018
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical studyAndrew Brenner, Richard Zuniga, Jessica D Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcomaSant P Chawla, Lee D Cranmer, Brian A Van Tine, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
Critical Care (London, England)|May 5, 2023
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trialPatrick M Wieruszewski, Rinaldo Bellomo, Laurence W Busse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesGlen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Pageof 2